Código QR (código de barras bidimensional)

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; howeve...

ver descrição completa

Na minha lista:
Principais autores: Josephine Bourner, Michel Vaillant, Alex Paddy Abdel Salam, Marie Jaspard, Camille Fritzell, Shevin T. Jacob, Tom E. Fletcher, Michael Ramharter, Nnennaya Ajayi, Sylvanus Okogbenin, Cyril Erameh, Donald Grant, Robert Samuels, Oladele Oluwafemi Ayodeji, Armand Sprecher, Bronner P. Gonçalves, Tansy Edwards, Piero Olliaro
Formato: Artigo
Idioma:Inglês
Publicado em: Centers for Disease Control and Prevention 2025-02-01
coleção:Emerging Infectious Diseases
Assuntos:
Lassa fever
clinical trials
viruses
phase II/III multicenter randomized controlled platform trial
Acesso em linha:https://wwwnc.cdc.gov/eid/article/31/2/24-0251_article
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados